| Ytd | 199.80% | |
| 1y | 783.99% |
| Open | 29.55 | Prev Close | 30.05 | Low | 28.56 | High | 29.60 | Mkt Cap | 3.71B |
| Vol | 175.57K | Avg Vol | 1.33M | EPS | -3.92 | P/E | -7.67 | Forward P/E | -9.58 |
| Beta | -0.73 | Short Ratio | 8.48 | Inst. Own | 99.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 24.23 | 200-d Avg | 19.03 | 1yr Est | 40.10 |
ALMS News
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeuci
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory disea
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases us
Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & U
Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoria
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a
Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at be
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality o
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psori
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of env
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-s
AXQ Capital LP bought a new stake in Alumis Inc. (NASDAQ: ALMS) in the third quarter, according to t
Credit Industriel ET Commercial lessened its holdings in shares of Alumis Inc. (NASDAQ: ALMS) by 36.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-st
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases w
Alumis Inc. (NASDAQ: ALMS - Get Free Report) was the target of a significant growth in short interes
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap
